Free Trial

Squarepoint Ops LLC Acquires New Position in Enhabit, Inc. (NYSE:EHAB)

Enhabit logo with Medical background

Squarepoint Ops LLC bought a new stake in Enhabit, Inc. (NYSE:EHAB - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 23,660 shares of the company's stock, valued at approximately $185,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Deerfield Management Company L.P. Series C lifted its holdings in shares of Enhabit by 0.3% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 5,010,972 shares of the company's stock valued at $39,136,000 after buying an additional 13,226 shares during the period. 8 Knots Management LLC raised its position in Enhabit by 16.4% during the fourth quarter. 8 Knots Management LLC now owns 4,430,898 shares of the company's stock valued at $34,605,000 after acquiring an additional 623,602 shares in the last quarter. AREX Capital Management LP lifted its holdings in Enhabit by 2.0% in the fourth quarter. AREX Capital Management LP now owns 2,490,795 shares of the company's stock valued at $19,453,000 after acquiring an additional 48,874 shares during the period. Systematic Financial Management LP boosted its position in Enhabit by 8.6% in the 4th quarter. Systematic Financial Management LP now owns 1,996,113 shares of the company's stock worth $15,590,000 after purchasing an additional 157,914 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Enhabit by 12.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,953,941 shares of the company's stock worth $15,260,000 after purchasing an additional 213,774 shares during the period.

Enhabit Price Performance

Shares of NYSE:EHAB traded down $0.04 during trading on Monday, reaching $10.76. The stock had a trading volume of 301,842 shares, compared to its average volume of 457,768. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.46 and a current ratio of 1.46. The business has a fifty day moving average price of $9.01 and a 200-day moving average price of $8.52. The stock has a market cap of $544.85 million, a PE ratio of -4.64 and a beta of 1.80. Enhabit, Inc. has a 1-year low of $6.85 and a 1-year high of $10.91.

Enhabit (NYSE:EHAB - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of $0.07 by $0.03. The company had revenue of $259.90 million for the quarter, compared to analyst estimates of $266.11 million. Enhabit had a positive return on equity of 1.67% and a negative net margin of 11.24%. On average, equities analysts forecast that Enhabit, Inc. will post 0.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group restated a "buy" rating on shares of Enhabit in a research report on Thursday, March 6th.

Read Our Latest Stock Report on EHAB

About Enhabit

(Free Report)

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.

Further Reading

Institutional Ownership by Quarter for Enhabit (NYSE:EHAB)

Should You Invest $1,000 in Enhabit Right Now?

Before you consider Enhabit, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enhabit wasn't on the list.

While Enhabit currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Analysts Are Watching These 4 Penny Stocks—You Should Too
Congress Is Pouring Millions Into These 6 Surprising Stocks
3 Dirt-Cheap Stocks in a Market That’s Getting Expensive

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines